Cerebrolysin (215 mg/mL, 10 mL)

Cerebrolysin is described as a peptide/amino-acid mixture derived from porcine brain proteins, formulated to cross the blood–brain barrier and support neuronal health. The article frames it as having neuroprotective and neurotrophic actions—supporting synaptic connectivity and repair-focused signaling. Educational context only.

Route & Frequency (as described):
Cerebrolysin is described as administered by intramuscular (IM) or intravenous (IV) injection (not oral). Protocols vary by condition severity, commonly using daily dosing or 5×/week schedules.

Caution (as noted in the article):
• Dose selection is described as condition- and severity-dependent; the article notes analyses reporting modest benefits in some settings and the possibility of serious non-fatal adverse effects.
• Special note included: avoid “very high doses” (example given >80 mL) at initiation to reduce the chance of negative reactions.
• The article also recommends use under medical supervision due to potential medication interactions.

Reconstitution / Handling:
The article presents Cerebrolysin as an injectable solution (IM/IV) and does not describe vial reconstitution with bacteriostatic water. Typical handling in this context:
• Use aseptic technique; inspect solution for clarity and packaging integrity.
• Use immediately after opening an ampoule/vial when applicable; do not “save” opened containers unless the manufacturer explicitly allows it.
• Store and protect from light per the product label/spec sheet.

CAS Number: 12656-61-0

PubChem CID: 472407974

Synonyms: Cerebrolyzin, FPE-1070, Renacenz, 37KZM6S21G

As a naturally occurring peptide mixture, Cerebrolysin lacks a single molecular structure. The FDA granted it orphan designation for frontotemporal dementia and ALS, reflecting its therapeutic promise in rare neurological diseases.

Principal Components

• Brain-Derived Neurotrophic Factor (BDNF)
• Glial Cell Line-Derived Neurotrophic Factor (GDNF)
• Ciliary Neurotrophic Factor (CNTF)
• Nerve Growth Factor (NGF)

• Brain-Derived Neurotrophic Factor (BDNF)
• Glial Cell Line-Derived Neurotrophic Factor (GDNF)
• Ciliary Neurotrophic Factor (CNTF)
• Nerve Growth Factor (NGF)

BDNF: Supports neuron and synapse growth, influences stress response, and is implicated in psychiatric and neurodegenerative research.

GDNF: Sustains dopaminergic and motor neurons, offering avenues for Parkinson’s disease and ALS exploration.

CNTF: Facilitates neurotransmission and astrocyte development; investigated for ALS, appetite regulation, and retinal degeneration.

NGF: Regulates sensory and sympathetic neuron survival, immune modulation, and pancreatic beta-cell protection.

Dementia & Alzheimer’s: Trials report cognitive improvements lasting months after treatment, reductions in neuropsychiatric symptoms, and correlations between symptom relief and lowered amyloid-beta production.

Parkinson’s Disease: GDNF content protects dopaminergic neurons, with controlled-release delivery showing broad motor and biochemical benefits in animal studies.

Stroke & Brain Injury: Administration within 72 hours post-stroke enhances recovery, particularly when combined with rehabilitation. Severe stroke cases exhibit the greatest functional gains.

Traumatic Injury & Cerebral Palsy: Pediatric and adult studies highlight improvements in cognition and motor control when Cerebrolysin accompanies structured therapy programs.

Rodent models of chronic migraine and neuropathic pain show decreases in pro-inflammatory cytokines (TNF-α, IL-1β) and mitigation of pain behaviors after Cerebrolysin administration, hinting at novel therapeutic directions.

Cerebrolysin’s peptide constituents support neuron survival, neuroplasticity, and neurotransmitter modulation. Evidence spans ALS, Alzheimer’s, Parkinson’s, stroke, traumatic brain injury, and chronic pain. Ongoing research explores long-term neuroprotection and potential cognitive enhancement applications.

PubMed

Article Author :

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.